Wednesday, August 1, 2012
Lixte Biotechnology Holdings Inc., of East Setauket, N.Y., said the FDA cleared the firm for a Phase I trial of cancer compound LB-100. The company also said it raised $2.5 million to initiate the trial and continue drug discovery research through an offering to holders of warrants for exercising their rights in cash.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.